Feedback / Questions
AB-1015 - ArsenalBio
https://www.businesswire.com/news/home/20220906005150/en/Arsenal-Biosciences-Closes-220-Million-Series-B-Financing-to-Advance-Programmable-Cell-Therapy-Programs-into-Clinical-Development
Sep 6, 2022
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev